home

STRATEGIC ADVISORY GROUP OF EXPERTS ON IMMUNIZATION CONVENED BY THE WORLD HEALTH ORGANIZATION RECOMMENDS USE OF SANOFI PASTEUR'S DENGUE VACCINE IN ENDEMIC COUNTRIES

RegulatorSanofi2016-04-18 11:39 Read   76

Sanofi and its vaccines global business unit Sanofi Pasteur, announced today that the Strategic Advisory Group of Experts on Immunization (SAGE) has issued its recommendations to the WHO on the use of Dengvaxia® dengue vaccine.

Exclusive: Valeant calls in investment banks to weigh options - sources

EVENTSreuters2016-04-18 11:39 Read   65

Valeant Pharmaceuticals International Inc (VRX.TO) has brought in investment banks to review its options amid interest from buyout firms and other companies in a number of its businesses, according to people familiar with the matter.

What does 'breakthrough' mean to docs and consumers? It's not the FDA definition

Commentsfiercepharma2016-04-18 11:14 Read   63

According to the dictionary, the word breakthrough means “a sudden, dramatic and important discovery or development.” However, what many doctors don’t know is that it doesn’t have the same meaning in the FDA drug approval process. 

New York AG sues insurer over restrictive hep C coverage

Commentsfiercepharma2016-04-18 11:11 Read   65

The New York State Attorney General has already taken some steps to find out why insurers are limiting coverage of pricey hep C meds to the sickest patients but has stopped short of suing companies for their decisions. Now, he’s stepping up his fight.

WuXi AppTec Acquires Crelux

EVENTSprnewswire2016-04-18 11:04 Read   65

WuXi AppTec, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has acquired Crelux GmbH, a leading structure based drug discovery provider based in Munich, Germany.

Novel drugs and rare diseases drive US prescription drug spend

Commentspmlive2016-04-18 10:52 Read   70

Spending on prescription drugs in the US reached a new record last year of $310bn, rising 8.5% and driven by new cancer and hepatitis C therapies.

Merck drops once-weekly diabetes drug in US and EU

EVENTSpmlive2016-04-18 10:41 Read   73

Merck & Co will no longer file for approval of once-weekly diabetes drug omarigliptin in the US or Europe, even though it is already on the market in Japan.

Only Half of Rectal Cancer Patients Get Recommended Treatment: Study

Commentsdrugs2016-04-18 10:34 Read   63

Despite the increasing use of a standard therapy for rectal cancer in the United States, only slightly more than half of patients receive it, a new study finds.

Sunscreen Delays Melanoma in Mice, Researchers Say

FrontierDRUGS2016-04-18 10:28 Read   60

Applying 30 SPF sunscreen to mice before they were exposed to ultraviolet-B (UVB) radiation delayed the development of melanoma, researchers report.

GlaxoSmithKline Selects TierPoint to Support Global Data Consolidation and Recovery Operations

Frontiermarketwired2016-04-18 10:18 Read   92

TierPoint, a leading national provider of hybrid IT solutions, announced that it has been selected by GlaxoSmithKline (GSK) to support the company's global data consolidation and protection initiatives.

Gilead hep C cocktail cures a pocket of drug-resistant cases

Commentsfiercebiotech2016-04-18 10:09 Read   92

Gilead has already provided a painless cure for the average hep C patient. Now they’re going after the final pocket of patients who are the toughest to treat.

Carbylan Therapeutics Announces Decision to Pursue Strategic Transaction

Frontierglobenewswire2016-04-18 10:05 Read   60

Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company, announced today that it has suspended further clinical development of Hydros-TA and that it is actively pursuing a strategic transaction, including a merger or acquisition of the company.